APA (7th ed.) Citation

CR, M., N, P., P, P., S, J., F, G., F, D., . . . M, H. (2026). Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: Long-term results from the DisCoVeRy trial. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 32(4), 618. https://doi.org/10.1016/j.cmi.2025.12.014

Chicago Style (17th ed.) Citation

CR, Massonnaud, et al. "Efficacy, Safety, Pharmacokinetics, Immunogenicity, and Serum Neutralizing Activity of AZD7442 (tixagevimab-cilgavimab) in Patients Hospitalized with COVID-19: Long-term Results from the DisCoVeRy Trial." Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 32, no. 4 (2026): 618. https://doi.org/10.1016/j.cmi.2025.12.014.

MLA (9th ed.) Citation

CR, Massonnaud, et al. "Efficacy, Safety, Pharmacokinetics, Immunogenicity, and Serum Neutralizing Activity of AZD7442 (tixagevimab-cilgavimab) in Patients Hospitalized with COVID-19: Long-term Results from the DisCoVeRy Trial." Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 32, no. 4, 2026, p. 618, https://doi.org/10.1016/j.cmi.2025.12.014.